[开放获取]    中国麻风分子和免疫诊断专家共识（2024版）

doi:10.35541/cjd.20230376

中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (11): 969-975.doi: 10.35541/cjd.20230376

[开放获取] 中国麻风分子和免疫诊断专家共识（2024版）

中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟中国麻风防治协会皮肤性病检验与诊断分会

中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟中国麻风防治协会皮肤性病检验与诊断分会

收稿日期:2023-06-28 修回日期:2024-09-23 发布日期:2024-10-31
通讯作者: 王洪生 E-mail:whs33@vip.sina.com
基金资助:
国家自然科学基金（81972950）；江苏省科教能力提升工程项目（ZDXYS202204）

-Expert consensus on the molecular and immunological diagnosis of leprosy in China （2024）

Mycobacteriosis Research Group, China “Belt and Road” Dermatology Alliance; Division of Dermatology and STI Diagnosis, Chinese Association on Leprosy

Mycobacteriosis Research Group, China “Belt and Road” Dermatology Alliance; Division of Dermatology and STI Diagnosis, Chinese Association on Leprosy

Received:2023-06-28 Revised:2024-09-23 Published:2024-10-31
Contact: Wang Hongsheng E-mail:whs33@vip.sina.com
Supported by:
National Natural Science Foundation of China （81972950）; Jiangsu Province Capability Improvement Project through Science, Technology and Education （ZDXYS202204）

摘要/Abstract

摘要： 【摘要】麻风是由麻风分枝杆菌感染引起的慢性传染性疾病，目前诊断主要依据临床表现和实验室检查，其中实验室检查主要包括皮肤涂片查菌和皮肤损害组织学检查。但部分麻风疑似患者，如少菌型、纯神经炎型患者，按传统实验室检查无法诊断，有必要利用分子和免疫学检查协助诊断。本共识在参考国内外麻风诊断相关文献、指南基础上编写，旨在促进麻风早期精准诊断和治疗。

关键词: 麻风, 早期诊断, 免疫学试验, 分子诊断技术, 抗药性, 细菌

Abstract: 【Abstract】 Leprosy is a chronic infectious skin disease caused by Mycobacterium leprae. Traditionally, its diagnosis mainly relies on clinical manifestations and laboratory examinations which include slit-skin smears and histopathological examinations of skin biopsies. As to some suspected leprosy cases, such as paucibacillary leprosy or pure neural leprosy cases, it is difficult to diagnose using traditional laboratory tests, thus molecular and immunological examinations are necessary for auxiliary diagnosis. This expert consensus was developed based on Chinese and international literature and guidelines on leprosy diagnosis, aiming to promote early and precise diagnosis and treatment of leprosy.

Key words: Leprosy, Early diagnosis, Immunologic tests, Molecular diagnostic techniques, Drug resistance, bacterial

中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟中国麻风防治协会皮肤性病检验与诊断分会. [开放获取] 中国麻风分子和免疫诊断专家共识（2024版）[J]. 中华皮肤科杂志, 2024,57(11):969-975. doi:10.35541/cjd.20230376

Mycobacteriosis Research Group, China “Belt and Road” Dermatology Alliance, Division of Dermatology and STI Diagnosis, Chinese Association on Leprosy. -Expert consensus on the molecular and immunological diagnosis of leprosy in China （2024）[J]. Chinese Journal of Dermatology, 2024, 57(11): 969-975.doi:10.35541/cjd.20230376

参考文献 44

［1］	Britton WJ, Lockwood DN. Leprosy［J］. Lancet, 2004,363（9416）:1209⁃1219. doi: 10.1016/S0140⁃6736（04）15952⁃7.
［2］	World Health Organization, Regional Office for South⁃East Asia. Guidelines for the diagnosis, treatment and prevention of leprosy［EB/OL］. （2018⁃10⁃06）［2023⁃06⁃28］. https://iris.who.int/handle/10665/274127.
［3］	World Health Organization. Global leprosy （Hansen disease） update, 2022: new paradigm⁃control to elimination［EB/OL］. （2023⁃09⁃14）［2024⁃09⁃15］. https://www.who.int/publications⁃detail⁃redirect/who⁃wer9837⁃409⁃430.
［4］	Srinivas G, Muthuvel T, Lal V, et al. Risk of disability among adult leprosy cases and determinants of delay in diagnosis in five states of India: a case⁃control study［J］. PLoS Negl Trop Dis, 2019,13（6）:e0007495. doi: 10.1371/journal.pntd.0007495.
［5］	中华人民共和国国家卫生健康委员会. WS 291⁃2018. 麻风病诊断［S/OL］.［2018⁃03⁃30］. https://www.nhc.gov.cn/wjw/s9491/201803/a8580254187c4f32bb8e5cc10cb9ea38.shtml.
［6］	Jiang H, Shi Y, Chokkakula S, et al. Utility of multi⁃target nested PCR and ELISPOT assays for the detection of paucibacillary leprosy: a possible conclusion of clinical laboratory misdiagnosis［J］. Front Cell Infect Microbiol, 2022,12:814413. doi: 10.3389/fcimb.2022.814413.
［7］	Martinez AN, Talhari C, Moraes MO, et al. PCR⁃based techniques for leprosy diagnosis: from the laboratory to the clinic［J］. PLoS Negl Trop Dis, 2014,8（4）:e2655. doi: 10.1371/journal.pntd.0002655.
［8］	Chauffour A, Morel F, Reibel F, et al. A systematic review of Mycobacterium leprae DNA gyrase mutations and their impact on fluoroquinolone resistance［J］. Clin Microbiol Infect, 2021,27（11）:1601⁃1612. doi: 10.1016/j.cmi.2021.07.007.
［9］	Marques LÉC, Frota CC, Quetz JDS, et al. Evaluation of 16S rRNA qPCR for detection of Mycobacterium leprae DNA in nasal secretion and skin biopsy samples from multibacillary and paucibacillary leprosy cases［J］. Pathog Glob Health, 2018,112（2）:72⁃78. doi: 10.1080/20477724.2017.1415736.
［10］	Alifano P, Palumbo C, Pasanisi D, et al. Rifampicin⁃resistance, rpoB polymorphism and RNA polymerase genetic engineering［J］. J Biotechnol, 2015,202:60⁃77. doi: 10.1016/j.jbiotec.2014. 11.024.
［11］	Liesack W, Pitulle C, Sela S, et al. Nucleotide sequence of the 16S rRNA from Mycobacterium leprae［J］. Nucleic Acids Res, 1990,18（18）:5558. doi: 10.1093/nar/18.18.5558.
［12］	Li W, Matsuoka M, Kai M, et al. Real⁃time PCR and high⁃resolution melt analysis for rapid detection of Mycobacterium leprae drug resistance mutations and strain types［J］. J Clin Microbiol, 2012,50（3）:742⁃753. doi: 10.1128/JCM.05183⁃11.
［13］	Li X, Li G, Yang J, et al. Drug resistance （dapsone, rifampicin, ofloxacin） and resistance⁃related gene mutation features in leprosy patients: a systematic review and meta⁃analysis［J］. Int J Mol Sci, 2022,23（20）:12443. doi: 10.3390/ijms232012443.
［14］	Cambau E, Carthagena L, Chauffour A, et al. Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy［J］. Clin Infect Dis, 2006,42（2）:238⁃241. doi: 10.1086/498506.
［15］	Comas I, Borrell S, Roetzer A, et al. Whole⁃genome sequencing of rifampicin⁃resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes［J］. Nat Genet, 2011,44（1）:106⁃110. doi: 10.1038/ng.1038.
［16］	Wu Z, Wang C, Wang Z, et al. Risk factors for dapsone resistance in leprosy patients: a systematic meta⁃analysis［J］. J Glob Antimicrob Resist, 2022,30:459⁃467. doi: 10.1016/j.jgar. 2022.05.015.
［17］	Wang C, Wu Z, Jiang H, et al. Global prevalence of resistance to rifampicin in Mycobacterium leprae: a meta⁃analysis［J］. J Glob Antimicrob Resist, 2022,31:119⁃127. doi: 10.1016/j.jgar.2022. 08.021.
［18］	Cambau E, Saunderson P, Matsuoka M, et al. Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009⁃15［J］. Clin Microbiol Infect, 2018,24（12）:1305⁃1310. doi: 10.1016/j.cmi.2018.02.022.
［19］	Chokkakula S, Chen Z, Wang L, et al. Molecular surveillance of antimicrobial resistance and transmission pattern of Mycobacterium leprae in Chinese leprosy patients［J］. Emerg Microbes Infect, 2019,8（1）:1479⁃1489. doi: 10.1080/22221751. 2019.1677177.
［20］	Freitas AA, Oliveira RM, Hungria EM, et al. Alterations to antigen⁃specific immune responses before and after multidrug therapy of leprosy［J］. Diagn Microbiol Infect Dis, 2015,83（2）:154⁃161. doi: 10.1016/j.diagmicrobio.2015.06.021.
［21］	do Carmo Gonçalves A, Hungria EM, Freitas AA, et al. Leprosy surveillance study in a highly endemic Brazilian area using leprosy specific serologic tests and IFNγ whole blood assay［J］. Eur J Clin Microbiol Infect Dis, 2020,39（12）:2345⁃2360. doi: 10.1007/s10096⁃020⁃03979⁃5.
［22］	Hungria EM, Freitas AA, Pontes MA, et al. Antigen⁃specific secretion of IFNγ and CXCL10 in whole blood assay detects Mycobacterium leprae infection but does not discriminate asymptomatic infection from symptomatic leprosy［J］. Diagn Microbiol Infect Dis, 2017,87（4）:328⁃334. doi: 10.1016/j.diagmicrobio.2017.01.002.
［23］	Chen X, You YG, Yuan YH, et al. Evaluation of antigen⁃specific immune responses for leprosy diagnosis in a hyperendemic area in China［J］. PLoS Negl Trop Dis, 2018,12（9）:e0006777. doi: 10.1371/journal.pntd.0006777.
［24］	Chen X, You YG, Yuan YH, et al. Host immune responses induced by specific Mycobacterium leprae antigens in an overnight whole⁃blood assay correlate with the diagnosis of paucibacillary leprosy patients in China［J］. PLoS Negl Trop Dis, 2019,13（4）:e0007318. doi: 10.1371/journal.pntd.0007318.
［25］	Wang H, Liu W, Jin Y, et al. Detection of antibodies to both M. leprae PGL⁃I and MMP⁃II to recognize leprosy patients at an early stage of disease progression［J］. Diagn Microbiol Infect Dis, 2015,83（3）:274⁃277. doi: 10.1016/j.diagmicrobio.2015. 07.012.
［26］	Le W, Haiqin J, Danfeng H, et al. Monitoring and detection of leprosy patients in Southwest China: a retrospective study, 2010⁃2014［J］. Sci Rep, 2018,8（1）:11407. doi: 10.1038/s41598⁃018⁃29753⁃4.
［27］	Duthie MS, Raychaudhuri R, Tutterrow YL, et al. A rapid ELISA for the diagnosis of MB leprosy based on complementary detection of antibodies against a novel protein⁃glycolipid conjugate［J］. Diagn Microbiol Infect Dis, 2014,79（2）:233⁃239. doi: 10.1016/j.diagmicrobio.2014.02.006.
［28］	Devides AC, Rosa PS, de Faria Fernandes Belone A, et al. Can anti⁃PGL⁃1 and anti⁃NDO⁃LID⁃1 antibody titers be used to predict the risk of reactions in leprosy patients?［J］. Diagn Microbiol Infect Dis, 2018,91（3）:260⁃265. doi: 10.1016/j.diagmicrobio.2018.03.002.
［29］	Canene⁃Adams K. General PCR［J］. Methods Enzymol, 2013,529:291⁃298. doi: 10.1016/B978⁃0⁃12⁃418687⁃3.00024⁃0.
［30］	Kamra E, Alam D, Singh V, et al. Diagnosis of urogenital tuberculosis by multiplex⁃nested PCR targeting mpt64 （Rv1980c） and IS6110: comparison with multiplex PCR and GeneXpert® MTB/RIF［J］. Lett Appl Microbiol, 2022,75（4）:857⁃868. doi: 10.1111/lam.13758.
［31］	Khosravi AD, Alami A, Meghdadi H, et al. Identification of Mycobacterium tuberculosis in clinical specimens of patients suspected of having extrapulmonary tuberculosis by application of nested PCR on five different genes［J］. Front Cell Infect Microbiol, 2017,7:3. doi: 10.3389/fcimb.2017.00003.
［32］	Chen X, He J, Liu J, et al. Nested PCR and the TaqMan SNP Genotyping Assay enhanced the sensitivity of drug resistance testing of Mycobacterium leprae using clinical specimens of leprosy patients［J］. PLoS Negl Trop Dis, 2019,13（12）:e0007946. doi: 10.1371/journal.pntd.0007946.
［33］	Wen Y, Xing Y, Yuan LC, et al. Whole⁃blood nested⁃PCR amplification of M. leprae⁃specific DNA for early diagnosis of leprosy［J］. Am J Trop Med Hyg, 2013,88（5）:918⁃922. doi: 10.4269/ajtmh.11⁃0253.
［34］	Banerjee S, Sarkar K, Gupta S, et al. Multiplex PCR technique could be an alternative approach for early detection of leprosy among close contacts⁃⁃a pilot study from India［J］. BMC Infect Dis, 2010,10:252. doi: 10.1186/1471⁃2334⁃10⁃252.
［35］	Martinez AN, Ribeiro⁃Alves M, Sarno EN, et al. Evaluation of qPCR⁃based assays for leprosy diagnosis directly in clinical specimens［J］. PLoS Negl Trop Dis, 2011,5（10）:e1354. doi: 10.1371/journal.pntd.0001354.
［36］	Kamal R, Dayal R, Katoch VM, et al. Analysis of gene probes and gene amplification techniques for diagnosis and monitoring of treatment in childhood leprosy［J］. Lepr Rev, 2006,77（2）:141⁃146.
［37］	Dayal R, Agarwal PK, Kalra K, et al. Diagnostic value of gene probes and its correlation with clinical profile of leprosy in children［J］. Indian Pediatr, 1994,31（12）:1521⁃1527.
［38］	Chen X, You YG, Yuan YH, et al. Evaluation of antigen⁃specific immune responses for leprosy diagnosis in a hyperendemic area in China［J］. PLoS Negl Trop Dis, 2018,12（9）:e0006777. doi: 10.1371/journal.pntd.0006777.
［39］	Wen Y, You YG, Yuan LC, et al. Evaluation of novel tools to facilitate the detection and characterization of leprosy patients in China［J］. Biomed Res Int, 2014,2014:371828. doi: 10.1155/2014/371828.
［40］	张秀明, 熊继红, 杨有业. 临床检验质量管理与标准操作程序［M］. 北京: 人民医学出版社, 2011.
［41］	中华人民共和国国家卫生健康委员会. GB/T 20468⁃2006. 临床实验室定量测定室内质量控制指南［S/OL］. （2006⁃09⁃01）［2024⁃10⁃21］. http://www.nhc.gov.cn/wjw/s9492/201409/8da8601c27e941b5a650cdfc0da97e2f.shtml.
［42］	王治国. 临床检验质量控制技术［M］. 北京: 人民卫生出版社, 2008.
［43］	中华人民共和国国家卫生和计划生育委员会. WS 288⁃2017肺结核诊断［J］. 结核与肺部疾病杂志, 2024,5（4）:376⁃378. doi: 10.19983/j.issn.2096⁃8493.2024022.
［44］	国家疾病预防控制局. 关于印发《全面消除麻风危害可持续发展规划（2024—2030年）》的通知［EB/OL］. ［2024⁃01⁃28］. https://www.ndcpa.gov.cn/jbkzzx/c100014/common/content/content_ 1750803396654190592.html.

[1]	张瑾陈绍椿尹跃平. 耐药淋球菌的备选治疗方案[J]. 中华皮肤科杂志, 2024, 57(3): 272-275.
[2]	吴澄宇王鹏康晓静. 卡波西肉瘤相关疱疹病毒鉴定与分型研究进展[J]. 中华皮肤科杂志, 2024, 57(3): 275-278.
[3]	李晓蝶朱琳洪毅勇黄影赖维龚子鉴. 不同实验条件对淋病奈瑟球菌体外转化效率的影响[J]. 中华皮肤科杂志, 2024, 57(3): 240-245.
[4]	卢琴黄美容杨慧张宁晴闵迅黄健. 鼻腔免疫淋病奈瑟球菌疫苗候选蛋白MetQ的免疫保护效果初步评估[J]. 中华皮肤科杂志, 2024, 57(3): 233-239.
[5]	郭蕾曹春艳方晓雅冯素英. 自身免疫性大疱病患者创面感染多重耐药菌现况及危险因素分析[J]. 中华皮肤科杂志, 2024, 57(2): 155-160.
[6]	马光荣谢红付刘家双周钟莲周淞麒黄莹雪李吉. 玫瑰痤疮患者小肠细菌过度生长情况调查及临床特征分析[J]. 中华皮肤科杂志, 2024, 57(2): 134-140.
[7]	李海洋林尽染刘庆梅倪春雅吴文育. 微生物群与头皮毛发疾病相关性研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 686-688.
[8]	孙培文王乐王洪生严良斌余美文. 2016—2020年中国麻风病流行病学特征分析[J]. 中华皮肤科杂志, 2023, 56(3): 204-209.
[9]	夏灵尹卢琴王小素黄美容闵迅黄健. 淋病奈瑟菌NGO2105蛋白660 ~ 1 468肽段的表达纯化及多克隆抗体的制备与鉴定[J]. 中华皮肤科杂志, 2023, 56(3): 216-221.
[10]	杨骥徐欣植李明. 皮肌炎的早期诊断和内脏损伤早期识别[J]. 中华皮肤科杂志, 2023, 56(2): 161-164.
[11]	夏瑞圆龙方园尹志强. 银屑病关节炎与甲银屑病相关性研究进展[J]. 中华皮肤科杂志, 2023, 56(11): 1061-1064.
[12]	李婷婷关猛猛赵娟康晓静. 单细胞转录组测序在黑素瘤研究中的应用[J]. 中华皮肤科杂志, 2023, 56(10): 977-981.
[13]	陈玉萍郑海林张之烽梅嬛刘维达刘沐桑. 南京某医院201株烟曲霉感染患者临床资料与唑类耐药情况回顾性分析[J]. 中华皮肤科杂志, 2022, 55(4): 316-320.
[14]	欧敏, 颜韵灵, 郑宝庆, 王晓华. 银屑病与肥胖相关性的研究进展[J]. 中华皮肤科杂志, 2022, 55(2): 181-184.
[15]	陈绍椿刘经纬周可尹跃平. 头孢曲松耐药淋病奈瑟菌株FC428的流行、耐药机制及应对策略[J]. 中华皮肤科杂志, 2022, 55(12): 1122-1126.

[开放获取] 中国麻风分子和免疫诊断专家共识（2024版）

-Expert consensus on the molecular and immunological diagnosis of leprosy in China （2024）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 44

相关文章 15

Metrics

本文评价

推荐阅读 10